Clinical trials
Early Breast Cancer clinical trials
Below are recruiting early breast cancer clinical trials, each written for real people, not researchers. We’re tracking 430 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05555888RecruitingPhase 2
Immunotherapy plus short-course radiation for early rectal cancer
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07230535Recruiting
Robotic vs standard mastectomy with DIEP reconstruction study
This trial compares how patients feel after open or robotic mastectomy combined with immediate DIEP flap reconstruction. It aims to see which approach improves wellbeing and recovery for women having this surgery.
BeaumontAges 18 years+ - NCT07084558Recruiting
Testing treatment guided by tumor DNA for hormone positive breast cancer
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Vienna, AustriaAges 18–100 - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT07832396Enrolling by invitation
Mammogram reminder study for women in Singapore
This study tests different ways to encourage women in Singapore to get a mammogram, which is an X-ray of the breast that helps find cancer early. If you are due for a mammogram, this study may help you get screened sooner.
SingaporeAges 50–69 - NCT06299202Recruiting
Predicting breast cancer treatment response with special mammogram
This study uses a special type of mammogram with contrast dye to see if it can predict how well breast cancer responds to chemotherapy before surgery. It's for people with HER2-positive or triple-negative breast cancer.
LyonAges 35 years+ - NCT07708571Recruiting
Coaching program for women on ribociclib and aromatase inhibitor
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
Augsburg, BavariaAges 18 years+ - NCT07448558Recruiting
Tailored exercise for breast cancer joint pain
This trial tests if a personalized exercise program can reduce joint and muscle pain caused by aromatase inhibitors in breast cancer patients. It may help you feel better during your hormone therapy.
BangkokAges 18 years+ - NCT07283107Enrolling by invitation
Increasing mammogram rates in Singaporean women
This trial tests different ways to encourage women in Singapore to get a mammogram (a breast X-ray to check for cancer early). You may be eligible if you are a Singaporean citizen aged 50–69, use the NUHS app, and have either never had a mammogram or are overdue for your next one.
SingaporeAges 50–69 - NCT02992574Recruiting
Radiation after mastectomy for certain node-negative breast cancers
This trial studies whether giving radiotherapy after a mastectomy helps prevent breast cancer coming back in women whose lymph nodes are not involved (or only very tiny spread). It may help reduce recurrence risk, especially for patients with higher-risk features despite node-negative early cancer.
Chandigarh, ChandigarhAges 18–80 - NCT06907095Recruiting
Early cancer detection study for high-risk individuals
This study tests if a simple blood or fluid test can find cancer early in people with a higher-than-average risk. If you have certain genetic mutations, a strong family history of cancer, or other high-risk conditions, you may be able to join.
VillejuifAges 18 years+ - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT07233499RecruitingPhase 2
Nebivolol for heart protection during breast cancer treatment
This trial tests if the drug nebivolol can protect the heart from damage caused by trastuzumab (Herceptin) in women with HER2-positive breast cancer. If effective, it may help prevent heart problems while still allowing cancer treatment.
CairoAges 18–65 - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Beverly Hills, CaliforniaAges 18 years+ - NCT05978648RecruitingPhase 2
Trilaciclib for early-stage HR-negative breast cancer after surgery
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Guangzhou, GangdongAges 18 years+ - NCT07832279Recruiting
Short versus long course radiation after breast-conserving surgery
This trial compares a one-week radiation treatment to a three-week treatment for early-stage breast cancer. It aims to see if the shorter course is as effective and safe, potentially making treatment more convenient.
ShanghaiAges 18–75 - NCT07243002Recruiting
Patient outcomes with ribociclib or abemaciclib for early breast cancer
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
LondonAges 18 years+ - NCT05559164RecruitingPhase 2
Statins to protect the heart during HER2 breast cancer treatment
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
Elizabeth, New JerseyAges 18 years+ - NCT06454864Recruiting
Exercise and Diet for Breast Cancer Survivors
This study tests whether a 6-month program combining weekly supervised exercise and dietary advice can improve health in breast cancer survivors who have completed initial treatments. It aims to help with weight, heart health, and overall well-being.
Toronto, OntarioAges Any age - NCT07764796Recruiting
Mobile health support for breast cancer screening in Kenya
This study tests a mobile health program that helps women in Nairobi, Kenya get screened for breast cancer earlier. It aims to guide women through the screening process and connect them with the right care.
Atlanta, GeorgiaAges 18 years+ - NCT07773818Recruiting
Improving early triple-negative breast cancer prediction
This study is part of a larger project collecting detailed genetic and other biological data from people with triple-negative breast cancer. The goal is to build better models to predict how the disease will progress and respond to treatment.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early breast cancer?
- Yes. Clin2 currently lists 430 recruiting early breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.